CommercialAdministrativeLow impact
11.08.12i, Surgery for Gynecomastia
Independence Blue Cross·Plastic Surgery, General Surgery·Medical Policy
We identified it
Jun 19, 2026
Summary
This is a routine annual policy reissue with no substantive changes to Independence Blue Cross's gynecomastia surgery coverage. The policy maintains existing medically necessary criteria (Grade II+ gynecomastia, age 18+, 3-month analgesic trial, documented glandular tissue, significant functional impact) and continues to classify liposuction-only treatment as experimental/investigational. CPT 19318 remains the covered code for reduction mammoplasty; CPT 15877 remains non-covered.
Action Required
No billing workflow changes required. This is an annual policy reissue with no substantive content modifications. Billing team should file this policy update in reference materials for continuity documentation. Continue applying existing coverage criteria: verify patient age (18+ or 18 months post-Tanner Stage 5), document Grade II+ gynecomastia, confirm 3-month analgesic trial, and ensure glandular tissue is documented by exam/imaging/biopsy. Continue denying claims for CPT 15877 as experimental/investigational and CPT 19300/19318 when criteria are not met or procedure is cosmetic-only.